Théa Invests Further In UK With Latest Dry Eye Launch
Théa Pharmaceuticals has expanded its growing OTC dry eye product range in the UK with the launch of a 3-in-1 preservative-free product.
You may also be interested in...
Thanks to double-digit growth in the cold and flu category and higher demand for analgesics, the UK’s OTC market grew by 4.5% to £2.87bn ($3.52bn), according to data from NielsenIQ. Looking ahead, Nielsen's consumer health expert Matt Carpenter suggests that consumers are now adopting "moving on" mindsets, which OTC firms need to take into account in their business strategies.
When it comes to assessing the safety of CBD in foods, the EU appears to be lagging behind the UK. Food Standards Agency CEO Emily Miles has noted that EFSA recently reached the same conclusions as the UK’s Committee on Toxicity did two years ago: there are still evidence gaps relating to CBD as a food. This may reassure UK operators that with the FSA further along in the assessment process it will not follow EFSA in suspending CBD novel food applications - but as expert Greer Deal notes, it's too soon to say.
Just because the use of a substance in a cosmetic product, in this case prostaglandin-derivative methylamide-dihydro-noralfaprostal, has a physiological effect does not mean it's a medicinal product by function, advises the Advocate General of the Court of Justice of the EU in a recent opinion. While the opinion does not bind the CJEU to any decision, it may impact discussions elsewhere with regards to these substances, for example in the US.